Waldenstr öm Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw. 2024 Jan;22(1D):e240001. doi: 10.6004/jnccn.2024.0001.ABSTRACTThe treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.PMID:38244272 | DOI:10.6004/jnccn.2024.0001

Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 20, 2024 Category: Cancer & Oncology Authors: Shaji K Kumar Natalie S Callander Kehinde Adekola Larry D Anderson Muhamed Baljevic Rachid Baz Erica Campagnaro Jorge J Castillo Caitlin Costello Christopher D'Angelo Benjamin Derman Srinivas Devarakonda Noura Elsedawy Alfred Garfall Kelly Godby Jens Hill Source Type: research